Columbia Care Sees Consensus Price Target Rise To $14.70

On August 12, Columbia Care Inc. (CSE: CCHW) reported its second-quarter financial results, wherein the company announced record revenues of $109.7 million, up 19% sequentially, with a gross margin of 43%. Gross profits rose 23.6% to $43.3 million, while Adjusted EBITDA came in at $16.4%, up 58% sequentially, and an EBITDA margin of 15%. The company reaffirmed its full year 2021 guidance of $500-$530 million in revenue and an Adjusted EBITDA of $95-$105 million.

Analysts made a few changes to their 12-month price target, raising the average consensus to $14.70 from $13.77 before the earnings. Columbia Care has 12 analysts covering the stock with 4 having strong buy ratings, 7 have buy ratings and a single analyst has a hold rating. The street high sits at $19 while the lowest comes in at $12.

Canaccord reiterated their buy rating and $15 price target on Columbia Care, saying that the company reported solid top-line growth and the company remains its top pick in their cannabis coverage.

Columbia Care generally came in line with Canaccord estimates, barely missing their revenue and Adjusted EBITDA expectations. Canaccord says that the revenue growth was boosted by a partial inclusion of Greem Leaf Medical. While Columbia Care reported California, Colorado, Massachusetts, Ohio, and Pennsylvania as its top 5 markets, Canaccord says its other operations in the states of Flordia, Arizona (+23), New Jersey (+20%), and Illinois (+15%) saw great growth.

Columbia Care saw its dispensary count increase to 77 retail locations with further locations in various stages of completion. The company also is adding to its Colorado exposure by acquiring Medicine Man for $42 million.

Below you can see Canaccord’s updated 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Verano: Haywood Securities Reiterates $36 Price Target

Earlier this week, Verano Holdings (CSE: VRNO) reported its first-quarter financial results. The company reported...

Friday, May 21, 2021, 10:31:00 AM

Uranium Royalty: Canaccord Gives Price Target A Lift After Physical Purchases

On September 15th, Uranium Royalty Corp. (TSXV: URC) announced that they purchased an additional 300,000...

Monday, September 20, 2021, 11:36:00 AM

Canaccord Reiterates Rating On CloudMD After Quarterly Results

On August 25, CloudMD Software & Services (TSXV: DOC) reported their second quarter financial results....

Saturday, August 28, 2021, 03:10:00 PM

BMO: IAMGOLD’s Review Of Cote Operations Expected To Be Negative

On April 18, BMO Capital Markets lowered their 12-month price target and downgraded IAMGOLD Corporation...

Tuesday, April 19, 2022, 05:16:00 PM

First Majestic: BMO Cuts Target To $9.50

Last week First Majestic Silver Corp (TSX: FR) announced its second quarter production results. The...

Thursday, July 28, 2022, 04:46:00 PM